Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.

Journal of cellular and molecular medicine - 1 Jan 2020

Chu Ming-Qiang, Zhang Ting-Juan, Xu Zi-Jun, Gu Yu, Ma Ji-Chun, Zhang Wei, Wen Xiang-Mei, Lin Jiang, Qian Jun, Zhou Jing-Dong

Abstract excerpt

Accumulating studies have proved EZH2 dysregulation mediated by mutation and expression in diverse human cancers including AML. However, the expression pattern of EZH2 remains controversial in acute myeloid leukaemia (AML). EZH1/2 expression and mutation were analysed in 200 patients with AML. EZH2 expression was significantly decreased in AML patients compared with normal controls but not for EZH1 expression....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Enhancer of Zeste Homolog 2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Hematopoietic Stem Cell Transplantation

Share to Kaplan-Meier Estimate

Share to Leukemia, Myeloid, Acute

Share to Nucleophosmin

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 31794134
DOI: 10.1111/jcmm.14855
PMCID: PMC6991666

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia.PMID 31794134Read ↗

The epigenetic role of EZH2 in acute myeloid leukemiaSemantic proximity Read ↗

EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemiaSemantic proximity Read ↗

EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patientsSemantic proximity Read ↗

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasmsSemantic proximity Read ↗

Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.Semantic proximity Read ↗

EZH2 in Myeloid Malignancies.Semantic proximity Read ↗

The role of EZH2 in the induction and maintenance of acute myeloid leukaemiaSemantic proximity Read ↗

Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AMLSemantic proximity Read ↗

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AMLSemantic proximity Read ↗

Correlation of EZH2 and related signaling molecules p-STAT3, p-ERK1/2, and MYC overexpression with H3K27 trimethylation associates differently to disease progression in JAK2 mutation -positive and -negative myeloid neoplasms.Semantic proximity Read ↗

Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.Semantic proximity Read ↗

EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.